Mumps - Pipeline Review, H2 2020
Mumps - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Pipeline Review, H2 2020, provides an overview of the Mumps (Infectious Disease) pipeline landscape.
Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Pipeline Review, H2 2020, provides an overview of the Mumps (Infectious Disease) pipeline landscape.
Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Mumps - Overview
Mumps - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mumps - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Mumps - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
GlaxoSmithKline Plc
Sinovac Biotech Ltd
Mumps - Drug Profiles
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mumps - Dormant Projects
Mumps - Product Development Milestones
Featured News & Press Releases
Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Mumps - Overview
Mumps - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mumps - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Mumps - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
GlaxoSmithKline Plc
Sinovac Biotech Ltd
Mumps - Drug Profiles
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mumps - Dormant Projects
Mumps - Product Development Milestones
Featured News & Press Releases
Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Mumps, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Mumps - Pipeline by Cadila Healthcare Ltd, H2 2020
Mumps - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Mumps - Pipeline by GlaxoSmithKline Plc, H2 2020
Mumps - Pipeline by Sinovac Biotech Ltd, H2 2020
Mumps - Dormant Projects, H2 2020
Number of Products under Development for Mumps, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Mumps - Pipeline by Cadila Healthcare Ltd, H2 2020
Mumps - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Mumps - Pipeline by GlaxoSmithKline Plc, H2 2020
Mumps - Pipeline by Sinovac Biotech Ltd, H2 2020
Mumps - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Mumps, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Beijing Minhai Biotechnology Co Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
GlaxoSmithKline Plc
Sinovac Biotech Ltd
Number of Products under Development for Mumps, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Beijing Minhai Biotechnology Co Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
GlaxoSmithKline Plc
Sinovac Biotech Ltd
